This website uses cookies. By continuing you are agreeing to our privacy policy.

Clinical Trials

ISABELA

Institution:

Multiple

Type:

Multi-Center Trial

Purpose:

To evaluate the efficacy of two doses of GLPG1690 in addition to local standard of care compared to placebo in subjects with idiopathic pulmonary fibrosis (IPF) as evaluated by the rate of decline of forced vital capacity (FVC) over a period of 52 weeks.

Dates:

November 5, 2018 - December 15, 2021

Disease:

Pulmonary Fibrosis

Register:

https://clinicaltrials.gov/ct2/results?cond=Pulmonary+Fibrosis&term=ISABELA

Contact:

Ann Fieuw
321-534-2900
[email protected]

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.